An exploratory biomarker sub-study determines bone metabolism serum markers such as P1NP, CTX, RANKL, OPG, sclerostin, sThy-1 at baseline, week 16 and week 28 during treatment of 50 patients with psoriasis with secukinumab (126). Here, TNFRSF11B is linked to psoriasis.